Fundraising Fox
Averna Therapeutics
Watertown, US · Founded 2022 · 62 employees on LinkedIn · 6 known investors
Find your way into Averna Therapeutics
Sign up to see every warm intro you have to Averna Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Averna Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Averna Therapeutics is a biotechnology company developing therapeutics. The page is a team bio profiling its CEO and board member.
Founders & leadership
RM
Richard MorrisChief Financial OfficerRichard Morris serves as Chief Financial Officer of Averna Therapeutics, a biotechnology company developing therapeutics. He has held senior financial leadership roles in pharmaceutical and biotech companies.
TM
Thomas M. BarnesCEO & Board Member
Board
RA
Roy AmariglioBoard director
NO
SS
MS
RP
Raju PrasadBoard director
TZ
HC
DM
Investors · 6
Deep Insightlisted by Deep InsightTel Aviv
How we know: Deep Insight's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Delos Capitallisted by Delos CapitalCambridge
How we know: Delos Capital's portfolio page · Not right? Tell us
Novartis Venture Fundlisted by Novartis Venture FundBasel · $5M – $25M
How we know: Novartis Venture Fund's portfolio page · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us
OrbiMedlisted by OrbiMedNew York · $1M – $75M
How we know: OrbiMed's portfolio page · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$85M disclosed across 1 round · 2024
▶$85MraisedMar 2026 · 13 investors · Other Health CareRule 506(b)
▶$85MraisedMar 2026 · 13 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Thomas BarnesDirector, Executive Officer
- Roy AmariglioDirector
- Nick OlsenDirector
- Stephen SquintoDirector
- Richard MorrisExecutive Officer
- Michal SilverbergDirector
- Raju PrasadDirector
- Tal ZaksDirector, Executive Officer
- Henry ChenDirector
- Dylan MorrisDirector
- Offering amount
- $85M
- Amount sold
- $85M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 7
OrnaOrna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications. The company leverages proprietary drug development expertise in oRNA and LNP technology platforms.
ロゴマーク：AIRNAAIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA. The company targets diseases where the underlying genetic mechanism is well-established and difficult to address with existing therapeutic approaches.
InspirnaInspirna is a clinical-stage biopharmaceutical company developing novel cancer drugs that target previously undruggable drivers of metastasis using its proprietary miRNA-DRIVEr platform. The company focuses on common cancers with high unmet need through small molecules and biologics.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
InnornaInnorna develops mRNA-based therapeutics built on a proprietary platform featuring a lipid library of over 100,000 ionizable lipid structures and targeted LNP delivery systems. The company's pipeline spans vaccines, protein replacement therapies for chronic metabolic diseases, and in vivo immunotherapies for autoimmune conditions, with four candidates in clinical trials.
Sionna TherapeuticsSionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.
Transcode TherapeuticsTransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.
Companies working in the same space as Averna Therapeutics.
In the news
Frequently asked questions
- What does Averna Therapeutics do?
- Averna Therapeutics is a biotechnology company developing therapeutics. The page is a team bio profiling its CEO and board member.
- Who are Averna Therapeutics's investors?
- Averna Therapeutics's investors include Deep Insight, Delos Capital, Novartis Venture Fund, OrbiMed, ARC VENTURES, Insight Partners.
- How much funding has Averna Therapeutics raised?
- Averna Therapeutics has disclosed $85M raised across 1 round.
- Where is Averna Therapeutics headquartered?
- Averna Therapeutics is headquartered in Watertown, US.